Colchicine vs. Placebo in Reducing CV Events; DOACs vs. Warfarin After TAVR; CSP vs. BiVP and Echo Response
In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Cardiac Surgery, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Prevention, Atherosclerotic Disease (CAD/PAD), Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Acute Heart Failure, Interventions and Coronary Artery Disease, Interventions and Imaging, Interventions and Vascular Medicine, Echocardiography/Ultrasound, Acute Coronary Syndromes, Vascular Medicine
Keywords: Ischemic Stroke, Coronary Artery Disease, Cardiovascular Diseases, Colchicine, Atherosclerosis, Secondary Prevention, National Cardiovascular Data Registries, STS/ACC TVT Registry, Anticoagulants, Transcatheter Aortic Valve Replacement, Warfarin, Cardiac Resynchronization Therapy, Heart Failure, Echocardiography, Electrophysiology, EaglesEyeView
